This large proportion of clinical failure costs deriving from antibiotic therapy most probably arises from the overlap existing between the failure of antibiotic therapy and clinical failure. Although this website clinical failure, a widely employed measure of drug effectiveness [2–4, 6, 7], is a composite of three different outcomes (antibiotic therapy switch, re-operation or death), in most instances it is driven by failure of first-line antibiotic therapy. In our study virtually all patients who clinically failed required second-line antibiotic therapy, while re-operation or death involved only a few patients (17.7% and 9.1%, respectively). This is consistent with the results of previous studies which have shown

that the majority of costs associated with clinical failure are due to antibiotic therapy [2, 7]. In most cases, clinical failure with antibiotic therapy is driven by unsuitable drug choice [3, 4, 6].

In the present study, although only “presumed” basing Cyclosporin A chemical structure on drug spectrum of coverage adequacy [1], appropriate antibiotic therapy was associated with a 78% chance of clinical success, compared with a 34% chance of clinical success associated with inappropriate therapy. Therefore, the role of antibiotic failure and inappropriateness of drug choice having a large influence on the occurrence of clinical failure could be inferred, as previously demonstrated [3, 7, 10]. As expected, the appropriateness of empiric antibiotic

therapy was more frequently reached with wide spectrum combination therapy. We found that multiple-drug empiric regimens were appropriate in 97% of cases compared with roughly 65% of single drug regimens. Moreover, patients who achieved clinical success were more likely to have received antibiotic combination therapy than those patients who failed antibiotic therapy, confirming previous findings [7]. On the other hand, the costs per day of antibiotic combination regimens were significantly higher than the costs of antibiotic monotherapy, Farnesyltransferase regardless of therapeutic outcome. Importantly, combination therapy was a strong independent predictor of increases in inpatient charges, causing approximately a 50% increase of mean hospitalization costs. Thus, the benefit/cost ratio underpinning the correct management of community-acquired cIAIs seems to be difficult to balance. Multiple antibiotic regimens aim to expand antimicrobial spectrum and to overcome increased bacterial resistance in community-acquired cIAIs [13, 14]. selleck inhibitor Recently, newly introduced wide spectrum agents, such as ertapenem and tygecicline, have been recommended [8] for use as first-line empiric antibiotic monotherapy regimens in stable, noncritically ill cIAIs patients with extended-spectrum beta-lactamase producing pathogens risk factors, factors that are becoming more frequently involved in community-acquired cIAIs [13, 14].